Adipocytokines, hepatic and inflammatory biomarkers and incidence of type 2 diabetes. the CoLaus study.

Publisher: Public Library of Science Country of Publication: United States NLM ID: 101285081 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1932-6203 (Electronic) Linking ISSN: 19326203 NLM ISO Abbreviation: PLoS One Subsets: MEDLINE

Original Publication: San Francisco, CA : Public Library of Science

Adipokines/*blood ; Biomarkers/*blood ; Diabetes Mellitus, Type 2/*blood ; Diabetes Mellitus, Type 2/*epidemiology ; Inflammation/*pathology ; Liver/*metabolism ; Liver/*pathology; Adult ; Aged ; Diabetes Mellitus, Type 2/pathology ; Female ; Humans ; Incidence ; Male ; Middle Aged ; Risk Factors ; Switzerland/epidemiology

Context: There is contradictory information regarding the prognostic importance of adipocytokines, hepatic and inflammatory biomarkers on the incidence of type 2 diabetes. The objective was to assess the prognostic relevance of adipocytokine and inflammatory markers (C-reactive protein - CRP; interleukin-1beta - IL-1β; interleukin-6- IL-6; tumour necrosis factor-α - TNF-α; leptin and adiponectin) and gamma-glutamyl transpeptidase (γGT) on the incidence of type 2 diabetes.
Methods: Prospective, population-based study including 3,842 non-diabetic participants (43.3% men, age range 35 to 75 years), followed for an average of 5.5 years (2003-2008). The endpoint was the occurrence of type 2 diabetes.
Results: 208 participants (5.4%, 66 women) developed type 2 diabetes during follow-up. On univariate analysis, participants who developed type 2 diabetes had significantly higher baseline levels of IL-6, CRP, leptin and γGT, and lower levels of adiponectin than participants who remained free of type 2 diabetes. After adjusting for a validated type 2 diabetes risk score, only the associations with adiponectin: Odds Ratio and (95% confidence interval): 0.97 (0.64-1.47), 0.84 (0.55-1.30) and 0.64 (0.40-1.03) for the second, third and forth gender-specific quartiles respectively, remained significant (P-value for trend = 0.05). Adding each marker to a validated type 2 diabetes risk score (including age, family history of type 2 diabetes, height, waist circumference, resting heart rate, presence of hypertension, HDL cholesterol, triglycerides, fasting glucose and serum uric acid) did not improve the area under the ROC or the net reclassification index; similar findings were obtained when the markers were combined, when the markers were used as continuous (log-transformed) variables or when gender-specific quartiles were used.
Conclusion: Decreased adiponectin levels are associated with an increased risk for incident type 2 diabetes, but they seem to add little information regarding the risk of developing type 2 diabetes to a validated risk score.

PLoS One. 2011;6(6):e19852. (PMID: 21674000)
Diabetes Care. 2004 May;27(5):1047-53. (PMID: 15111519)
Diabetes Care. 2009 Nov;32(11):2116-9. (PMID: 19720844)
Diabetologia. 2003 Mar;46(3):359-64. (PMID: 12687334)
Diabetologia. 2011 Oct;54(10):2552-60. (PMID: 21727999)
Am J Epidemiol. 2012 Sep 15;176(6):495-6. (PMID: 22875758)
Am J Epidemiol. 2011 Aug 1;174(3):364-74. (PMID: 21673124)
Atherosclerosis. 2012 Sep;224(1):274-9. (PMID: 22846611)
Hepatology. 2012 Sep;56(3):943-51. (PMID: 22505194)
Eur J Epidemiol. 2011 Jan;26(1):29-38. (PMID: 21188480)
BMC Cardiovasc Disord. 2008 Mar 17;8:6. (PMID: 18366642)
Diabetes. 2010 Mar;59(3):611-8. (PMID: 19959759)
Diabet Med. 2010 Oct;27(10):1116-23. (PMID: 20854378)
Clin Chem Lab Med. 2008;46(8):1175-9. (PMID: 18605954)
Diabetes Care. 2008 Jan;31 Suppl 1:S55-60. (PMID: 18165338)
Stat Med. 2008 Jan 30;27(2):157-72; discussion 207-12. (PMID: 17569110)
Diabetes Care. 2003 Jun;26(6):1745-51. (PMID: 12766104)
PLoS One. 2011;6(6):e21002. (PMID: 21695270)
Diabetes Res Clin Pract. 2004 May;64(2):99-106. (PMID: 15063602)
Am J Epidemiol. 2012 Sep 15;176(6):473-81. (PMID: 22875755)
Ann Intern Med. 2006 Jul 4;145(1):21-9. (PMID: 16818925)
J Clin Endocrinol Metab. 2004 Nov;89(11):5410-4. (PMID: 15531490)
Epidemiol Rev. 2011;33:46-62. (PMID: 21622851)
JAMA. 2009 Jul 8;302(2):179-88. (PMID: 19584347)
AIHAJ. 2001 Mar-Apr;62(2):195-8. (PMID: 11331991)
Arch Intern Med. 2012 Jan 23;172(2):188-9. (PMID: 22271131)
Diabetes. 2004 Mar;53(3):693-700. (PMID: 14988254)
Eur J Gen Pract. 2007;13(1):27-34. (PMID: 17366291)
Pancreas. 2007 Nov;35(4):343-7. (PMID: 18090240)
Ann Intern Med. 2009 Jun 2;150(11):741-51. (PMID: 19487709)
Diabet Med. 2010 Sep;27(9):1004-11. (PMID: 20722673)
Circulation. 2009 May 5;119(17):2408-16. (PMID: 19364974)
Obesity (Silver Spring). 2007 Jul;15(7):1841-50. (PMID: 17636103)
Diabetes. 2004 Sep;53(9):2473-8. (PMID: 15331562)
Diabetes Care. 2007 May;30(5):1200-5. (PMID: 17322479)
Am J Epidemiol. 2012 Sep 15;176(6):488-91. (PMID: 22875759)
Neuroimmunomodulation. 2010;17(1):39-46. (PMID: 19816056)
Am J Epidemiol. 2010 Aug 1;172(3):353-61. (PMID: 20562194)
Arch Intern Med. 2003 Jan 13;163(1):93-9. (PMID: 12523922)
Diabetologia. 2006 Sep;49(9):2086-96. (PMID: 16850292)
Diabetologia. 2010 Feb;53(2):247-53. (PMID: 19936701)
Clin Chem. 2010 Apr;56(4):537-41. (PMID: 20133890)
Diabetes Care. 2011 Aug;34(8):1863-8. (PMID: 21636799)
Cancer Epidemiol Biomarkers Prev. 2007 Nov;16(11):2464-70. (PMID: 18006938)
Diabetes. 2002 Apr;51(4):1131-7. (PMID: 11916936)
J Natl Cancer Inst. 2010 Nov 3;102(21):1618-27. (PMID: 20956782)
Arch Intern Med. 2006 Feb 13;166(3):350-6. (PMID: 16476877)
Horm Metab Res. 2009 Aug;41(8):626-9. (PMID: 19370507)
JAMA. 2007 Aug 15;298(7):776-85. (PMID: 17699011)
JAMA. 2001 Jul 18;286(3):327-34. (PMID: 11466099)
Diabetes. 2003 Mar;52(3):812-7. (PMID: 12606524)
PLoS One. 2010 Apr 09;5(4):e10100. (PMID: 20396381)

0 (Adipokines)
0 (Biomarkers)

Date Created: 20121220 Date Completed: 20130603 Latest Revision: 20220317

20231215

PMC3520903

10.1371/journal.pone.0051768

23251619